Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2020 financial results on Friday, November 6, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media and the general public can access a live webcast of the conference call through the link that will be posted on Elanco

Elanco Confirms Date and Conference Call for Third Quarter 2020 Financial Results Announcement

Palantir Technologies

Visa

You don't need to start with a fortune to chart a path toward financial independence.

4 Great Stocks You Can Buy With $300

Hedge fund Sachem Head Capital Management has built a $1.2 billion stake in Elanco Animal Health Inc and plans to push for changes at the company that makes medicines and vaccinations for pets and livestock, a person familiar with the matter said on Wednesday.

Sachem Head takes $1.2 billion position in Elanco, stock price surges

Elanco Animal Health Inc. ELAN, -1.10% said Wednesday it is restructuring its business just two months after closing the acquisition of Bayer Animal Health. The Greenfield, Indiana-based company said it expects to cut 900 jobs across nearly 40 countries, mostly in sales and marketing, but also in R&D, manufacturing and quality, and back office support.

Elanco Animal Health to cut 900 jobs in 40 countries in restructuring following acquisition of Bayer Animal Health

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE:ELAN) today announced its first business restructuring just two months following the closing of its acquisition of Bayer Animal Health. The company also noted it has started to de-lever by making a $100 million payment on its term loan. Elanco leadership has quickly evaluated the capabilities, structure and staffing of the combined business required to meet its goal of being an agile, fit-for-purpose global leader dedica

Elanco Announces Restructuring to Drive Synergies From Bayer Animal Health Acquisition

CrowdStrike

SSR Mining

Green Thumb Industries Inc.

A vacillating stock market can be your friend if you have cash at the ready and a long-term mindset.

Got $300? 4 Great Stocks to Buy in a Volatile Market

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020.

Elanco to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference

The acquisition of Bayer Animal Health establishes Elanco as the second-largest animal health company in the world.

This Pet Stock Just Bought an Animal Health Business for $7.6 Billion

Elanco Animal Health (NYSE: ELAN) shares are trading higher on Thursday after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and announced a price target of $31 per share.

Why Elanco Animal Health's Stock Is Trading Higher Today

Elanco Animal Health Inc (NYSE: ELAN) shares are trading higher on Tuesday after Goldman Sachs reinstated a Buy rating on the stock and announced a price target of $26.50 per share.

Why Elanco Animal's Stock Is Trading Higher Today

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health.

Elanco Closes Acquisition of Bayer Animal Health

Elanco Animal Health Incorporated (ELAN) CEO Jeff Simmons on Q2 2020 Results - Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 350.00% and 5.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Tops Q2 Earnings and Revenue Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the second quarter of 2020.

Elanco Animal Health Reports 2020 Second Quarter Results

New York, New York--(Newsfile Corp. - July 20, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated  ("Elanco" or "the Company") (NYSE: ELAN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Elanco securities between January 10, 2020 and May 6, 2020, inclusive (the ''Class Period'').

ELAN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Elanco Animal Health Incorporated and Lead Plaintiff Deadline: July 20, 2020

Los Angeles, California--(Newsfile Corp. - July 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN) ("Elanco" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S.

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Elanco Animal Health Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Elanco Animal Health Incorporated (NYSE: ELAN) between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”), of the important July 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Elanco investors under the federal securities laws.

ELAN FINAL DEADLINE TODAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Reminds Elanco Animal Health Incorporated Investors of Important July 20 Deadline in Securities Class Action – ELAN

NEW ORLEANS, July 19, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 20, 2020 to file lead plaintiff applications in a securities class action lawsuit.

ELANCO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Elanco Animal Health Incorporated - ELAN

NEW ORLEANS--(BUSINESS WIRE)--ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until July 20, 2020 to file lead plaintiff applications in a securities class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN), if they purchased the Company’s securities between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Indiana.

ELANCO 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Elanco Animal Health Incorporated - ELAN

Despite mediocre financial results, could a major upcoming acquisition be what this company needs to succeed?

Is Elanco Stock a Buy?

New York, New York--(Newsfile Corp. - July 17, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Elanco Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco Animal Health Incorporated To Contact The Firm

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 20, 2020 to file lead plaintiff applications in a securities class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN), if they purchased the Company’s securities between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”).

ELANCO 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Elanco Animal Health Incorporated - ELAN

Los Angeles, California--(Newsfile Corp. - July 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN) ("Elanco" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S.

DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Elanco Animal Health Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $ELAN #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) securities between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”).

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Elanco Animal Health Incorporated (ELAN)

Los Angeles, California--(Newsfile Corp. - July 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN) ("Elanco" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S.

MONDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Elanco Animal Health Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

News for Elanco Animal Health Inc Stock (ELAN)